Thromb Haemost 1980; 43(01): 058-060
DOI: 10.1055/s-0038-1650012
Original Article
Schattauer GmbH Stuttgart

Relationship of ADP-Induced Fibrinogen Binding to Platelet Shape Change and Aggregation Elucidated by Use of Colchicine and Cytochalasin B

Ellinor I Peerschke
The Department of Pathology, New York University Medical Center, New York, New York, U. S. A.
,
Marjorie B Zucker
The Department of Pathology, New York University Medical Center, New York, New York, U. S. A.
› Author Affiliations
Further Information

Publication History

Received 08 October 1979

Accepted 24 January 1980

Publication Date:
13 July 2018 (online)

Summary

ADP causes human, aspirin-treated, gel-filtered platelets to change from their native discoid shape to spiny spheres with pseudopods, bind 125I-labeled fibrinogen, and aggregate if shaken with sufficient fibrinogen. After destruction of the added ADP with the enzyme apyrase, the platelets revert to a disc shape and lose much of their bound fibrinogen. Colchicine (208 μM or 83 μg/ml) added to ADP-treated platelets before apyrase prevented restoration of the discoid shape but not the loss of bound fibrinogen. It did not inhibit ADP-induced shape change, aggregation, or fibrinogen binding. Cytochalasin B (0.02–0.2 μM or 0.01–0.10 μg/ml) prevented ADP-induced shape change but not ADP-induced fibrinogen binding or aggregation. Thus, these findings support earlier studies with thrombasthenic and EDTA-treated platelets and with normal platelets at low pH, or in the presence of EDTA to indicate that fibrinogen binding is associated with aggregability but not with platelet shape.

 
  • References

  • 1 Zucker MB, Zaccardi JB. Platelet shape change induced by adenosine diphosphate and prevented by adenosine monophosphate. Fed Proc 1964; 23: 299
  • 2 O'Brien JF, Heywood JB. Effect of aggregating agents and their inhibitors on the mean platelet shape. J Clin Path 1966; 19: 148-153
  • 3 Mustard JF, Packham MA, Kinlough-Rathbone RL, Perry DW, Regoeczi E. Fibrinogen and ADP-induced aggregation. Blood 1978; 52: 453-466
  • 4 Marguerie GA, Plow EF, Edgington TS. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem 1979; 254: 5357-5363
  • 5 Bennett JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest 1979; 64: 1393-1401
  • 6 Peerschke EI, Zucker MB, Grant RA, Egan JJ, Johnson MM. Correlation between fibrinogen binding to human platelets and platelet aggregability. Blood, May 1980
  • 7 Phillips DR, Agin PP. Platelet membrane defects in Glanzmann’s thrombasthenia. Evidence for decreased amounts of two major glycoproteins. J Clin Invest 1977; 60: 535-545
  • 8 White JG. Effect of colchicine and vinca alkaloids on human platelets. III. Influence on primary internal contraction and secondary aggregation. Am J Pathol 1969; 54: 467-478
  • 9 White JG. Platelet microtubules and microfilaments. Effects of cytochalasin B on structure and function. In: Aggregation Platelet, Caen J. (Ed.) Masson, Paris: 1971. p. 15-52
  • 10 Packham MA, Mustard JF. Clinical pharmacology of platelets. Blood 1977; 50: 555-573
  • 11 Walsh PN. Albumin density gradient separation and washing of platelets and study of platelet coagulant activities. Br J Haematol 1972; 22: 205-217
  • 12 Tangen O, Berman HJ, Marfey P. Gel filtration. A new technique for separation of blood platelets from plasma. Thromb Diath Haemorrh 1971; 25: 268-278
  • 13 White JG. Fine structural changes induced in platelets by adenosine diphosphate. Blood 1968; 31: 604-622
  • 14 Plow EF, Marguerie G, Edgington TS. Induction of the fibrinogen receptor on human platelets by epinephrine. Blood 1979; 54: 257